Please login to the form below
Vertex
This page shows the latest Vertex news and features for those working in and with pharma, biotech and healthcare.
Pioneering research collaboration seeks cure for cystic fibrosis
Previously, it worked with Vertex Pharmaceuticals to develop the small molecule drugs that focus on ‘fixing’ the protein in the cells of CF patients, but now has its eye on a
Latest news
-
Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
Vertex has released results from its phase 1/2 trial for VX-880, a stem-cell-derived therapy that restores insulin production. ... However, Vertex aims to avoid this problem by encapsulating the pancreatic cells to shield them from immune attack.
-
Vertex expands further into cell and genetic therapies with a deal worth up to $1.2bn
Vertex will also make an investment in Arbor in the form of a convertible note. ... The deal with Arbor further enhances Vertex’s focus on cell and genetic therapies.
-
Vertex to lead development of CRISPR Therapeutics-partnered gene therapy
as we bring forward our broad gene and cell-based therapeutics portfolio,” said Jeffrey Leiden, executive chairman of Vertex. ... Along with Vertex/CRISPR Therapeutics, bluebird bio is also seeking to bring its gene therapy LentiGlobin for SCD (bb1111)
-
Vertex gains FDA fast track designation for diabetes stem cell therapy
Vertex gained VX-880 from its previous acquisition of Semma Therapeutics for $950m in September 2019. ... This will help to protect the islet cells from immune rejection, Vertex said in a statement.
-
ASH 2020: Gilead eyes new Yescarta indication, Vertex/CRISPR make headway in sickle cell and more
Vertex/CRISPR Therapeutics make headway in sickle cell and beta thalassaemia. Also presenting data at ASH were Vertex and CRISPR Therapeutics, whose gene-editing therapy CTX001 scored some promising results in ... Reshma Kewalramani, chief executive
More from news
Approximately 62 fully matching, plus 84 partially matching documents found.
Latest Intelligence
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
including Shire/Takeda, Actelion/J&J, Sanofi Genzyme, Alexion, Amicus, BioMarin, Sarepta and Vertex.
-
Health trust in a COVID-19 world – a unique opportunity for pharma
There were also some high-profile reimbursement stand-offs between pharma and the NHS (eg, Vertex/Orkambi).
-
The Cystic Fibrosis Buyers’ Club
Just Treatment is also urging the UK government to override Vertex’s patent via compulsory licensing or Crown Use Licence. ... Meticulous preparations. The supply of the generic drug comes from Argentinian pharma company Gador, whose Lucaftor is a copy
-
Vertex: a vision of treating all CF patients worldwide draws closer
Its high prices are controversial, but Vertex also embodies the best of biopharma drug development. ... The failure of Proteostasis has led analysts to upgrade forecasts for Vertex’s own franchise.
-
The Orkambi row explained
Is Vertex’s price reasonable? This is the million dollar question, so to speak. ... October 2016: Orkambi negotiations between Vertex, the UK government and the NHS get underway.
More from intelligence
Approximately 6 fully matching, plus 21 partially matching documents found.
Latest appointments
-
New hires at bluebird bio, BioNTech and Provention Bio
He has also held sales, marketing and medical affairs leadership roles at Sarepta Therapeutics, Vertex Pharmaceuticals and Gilead Sciences.
-
Red Consultancy appoints MD in its health division
Prior to joining Red, she was seconded to Vertex Pharmaceuticals as director of communication for the North region, where she was responsible for UK, Ireland and Nordics.
-
Hanover Brussels appoints Aurélie Marchand as account director
In her new role, Marchand will report to Eatwell and she will oversee the group’s portfolio of clients, which includes Sanofi Pasteur and Vertex Pharmaceuticals.
-
Rubius Therapeutics strengthens senior team
He has spent 16 years at Novartis holding roles in human resources, marketing, and sales, and he has also served Vertex Pharmaceuticals in various positions.
-
Vertex poaches new finance chief from Ironwood Pharmaceuticals
Boston-based biotech company appoints Tom Graney. Vertex lured Tom Graney away from Ironwood Pharmaceuticals, appointing him as its new senior vice president and chief financial officer. ... Tom has the ideal blend of financial acumen, leadership skills,
More from appointments
Approximately 2 fully matching, plus 13 partially matching documents found.
Latest from PMHub
-
Frontera Group
Novartis Pharmaceuticals. Pfizer. Shire Pharmaceuticals. UCB . Vertex Pharmaceuticals.
-
Warehousing of HCV patients reaches new high
New drugs from Vertex (Incivek) and Merck (Victrelis) have been welcomed because they are more effective, but they still need to be given with Interferon.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Biogen and Happify Health team up to create digital platform for MS patients
- Myovant Sciences and Pfizer publish phase 3 results for endometriosis therapy
- Moderna to launch Innovation and Technology Center in the UK
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Gilead Sciences supports Kigali Declaration for neglected tropical diseases
- As the NHS turns 74, it launches its ‘biggest NHS Big Tea ever’ to raise funds
- FDA issues innovative proposal to increase nonprescription drug access
- European Commission approves potential new treatment for Pompe disease
- Connect to the conversation around mental health: A spotlight on physician burnout
- How understanding the rare disease patient’s lived experience creates better health communications
- A creative awakening – how pharma is bringing innovation to the patient journey
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Roche shares new positive Ocrevus data for MS patients
- FDA issues innovative proposal to increase nonprescription drug access
- Myovant Sciences and Pfizer publish phase 3 results for endometriosis therapy
- Annovis Bio’s lead therapeutic shows ‘significant improvements’ in Alzheimer’s, Parkinson’s
PMHub
90TEN
90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...
Latest intelligence
- Virtual MSL/Sales training programs and events
- Top 10 ways to leverage the Impetus InSite Platform® for internal MSL/Sales training programs and events...
- 6 trends shaping the future of personalized medicine
- Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
- Omnichannel strategies to revolutionize the healthcare professional experience
- Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the...
